Qiao Lei, Xu Zibo, Chen Yuheng, Chen Wenwei, Liang Yuan, Wei Yi, Wang Kang, Yu Yue, Yan Wei
Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, NHC Key Laboratory of Living Donor Liver Transplantation (Nanjing Medical University), Jiangsu Provincial Medical Innovation Center, Jiangsu Provincial Medical Key Laboratory, Nanjing, Jiangsu Province, China.
Department of Bioinformatics, Nanjing Medical University, Nanjing, China.
Front Cell Dev Biol. 2024 Jun 3;12:1407428. doi: 10.3389/fcell.2024.1407428. eCollection 2024.
The mortality of hepatocellular carcinoma (HCC) is on the rise globally, particularly in the Western world, with etiology gradually shifting from virus-related liver diseases to metabolic disorders such as non-alcoholic fatty liver disease. Early detection of HCC is challenging, and effective prognostic indicators are currently lacking, urgently necessitating reliable markers to assist in treatment planning and clinical management. Here, we introduce hepatocellular carcinoma senescence genes (HSG) to assess cellular senescence in HCC and devise a hepatocellular carcinoma senescence score (HSS) for prognostic prediction. Higher HSS levels signify poorer prognosis and increased tumor proliferation activity. Additionally, we observe alterations in the tumor immune microenvironment with higher HSS levels, such as increased infiltration of Treg, potentially providing a basis for immunotherapy. Furthermore, we identify key genes, such as PTTG1, within the senescence gene set and demonstrate their regulatory roles in HCC cells and Treg through experimentation. In summary, we establish a scoring system based on hepatocellular carcinoma senescence genes for prognostic prediction in HCC, potentially offering guidance for clinical treatment planning.
全球肝细胞癌(HCC)的死亡率正在上升,尤其是在西方世界,其病因正逐渐从病毒相关的肝脏疾病转变为代谢紊乱,如非酒精性脂肪性肝病。HCC的早期检测具有挑战性,目前缺乏有效的预后指标,迫切需要可靠的标志物来辅助治疗规划和临床管理。在此,我们引入肝细胞癌衰老基因(HSG)来评估HCC中的细胞衰老,并设计了一个肝细胞癌衰老评分(HSS)用于预后预测。较高的HSS水平表明预后较差且肿瘤增殖活性增加。此外,我们观察到HSS水平较高时肿瘤免疫微环境的改变,如调节性T细胞(Treg)浸润增加,这可能为免疫治疗提供依据。此外,我们在衰老基因集中鉴定出关键基因,如垂体瘤转化基因1(PTTG1),并通过实验证明了它们在HCC细胞和Treg中的调控作用。总之,我们建立了一个基于肝细胞癌衰老基因的评分系统用于HCC的预后预测,可能为临床治疗规划提供指导。